Serhat Özçelik, Mehmet Çelik, Evren Aydoğdu, Kadriye Aydın Tezcan, Naile Gökkaya, Mehmet Tiryaki, Dilek Yavuzer

Clinical, pathological and endocrinological evaluationof patients with microscopic transsphenoidal pituitarysurgery

Aim: Detailed evaluation of patients in preoperative stage is an important factor that reduces morbidity and mortality as well as theoperation itself. In our study, we aimed to examine clinically, pathologically and endocrinologically, the patients who were decided toundergo transsphenoidal surgery, in light of the literature. Materials and Methods: In this retrospective observational study, preoperative and pathological data of consecutive pituitaryadenoma patients who applied to our department from January 2019 to June 2020 and underwent transsphenoidal surgery withmicroscopic methods, were examined. Results: The study included a total of 31 patients. Distribution of patients in relation to pathological diagnoses was as follows:Functional pituitary adenoma (n: 15), non-functional adenoma (n: 11), apoplexy (n: 2), carcinoma metastasis (n: 2) andcraniopharyngioma (n: 1). No statistically significant difference was found between functional and non-functional adenomas, interms of tumor size, cavernous sinus invasion, Ki-67 index and p53 staining pattern (p> 0.05) whereas presence of suprasellarextension and visual field defect were significantly more in non-functional adenomas (p = 0.015, p = 0.045, respectively). Conclusion: Highly invasive character was detected in both functional and non-functional pituitary Ki-67 indexes were low in thestudy population, increased p53 expression was noticeable. We can state that the Ki-67 index may not be directly proportional tothe invasive behavior of the disease.

PDF

___

1. Raappana A, Koivukangas J, Ebeling T, et al. Incidence of pituitary adenomas in Northern Finland in 1992- 2007. J Clin Endocrinol Metab 2010;95:4268-75.
2. Tjörnstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol 2014;171:519-26.
3. Ertan Y, Sarsik B, Akalin T. Tipik ve atipik hipofiz adenomlarında hormon immunreaktivite dağılımı Turkish Journal of Pathology. 2009;25:106-11.
4. Chatzellis E, Alexandraki KI, Androulakis II, et al. Aggressive pituitary tumors. Neuroendocrinology 2015;101:87-104.
5. Youssef AS, Agazzi S, van Loveren HR. Transcranial surgery for pituitary adenomas. Neurosurgery 2005;57:168-75.
6. D’Haens J, Rompaey KV, Stadnik T, et al. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas. A retrospective comparison with traditional transsphenoidal microsurgery in the same institution. Surg Neurol 2009;72:336-40.
7. Klibanski A. Clinical practice. Prolactinomas. New England Journal of Medicine 2010;362:1219-26.
8. Türkiye Endokrinoloji ve Metabolizma Derneği, Hipofiz Hastalıkları Tanı, Tedavi ve İzlem Kılavuzu 2019. Ankara: Miki Yayıncılık; 2019:45-51.
9. Chaidarun SS, Klibanski A. Gonadotropinomas. Semin Reprod Med 2002;20:339-48.
10. Thakkar A, Kannan S, Hamrahian A, et al. Testicular "hyperstimulation" syndrome: a case of functional gonadotropinoma. Case Rep Endocrinol 2014;2014:194716.
11. Gorbacheva AM, Przhiyalkovskaya EG, Azizyan VN, et al. An ovarian hyperstimulation syndrome caused by gonadotropinoma in a young woman. Probl Endokrinol (Mosk) 2019;65:278-88.
12. Sav A, Rotondo F, Syro LV, et al. Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin North Am 2015;44:99-104
13. Salehi F, Agur A, Scheithauer BW, et al. Ki-67 in Pituitary Neoplasms: A Review--Part I. Neurosurgery 2009;65:429-37.
14. Thapar K, Scheithauer BW, Kovacs K, et al. P53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-71.
15. Basaran R, Onoz M, Bolukbasi FH, et al . Low o6- methylguanıne-dna methytransferase (mgmt) and pan-cytokeratın (pan-ck) expressıon vıa ımmunohıstochemıstry ın pıtuıtary adenomas Acta Endocrinol (Buchar) 2017;13:282-93.
16. Botelho CH, Magalhães AV, Mello PA, et al. Expression of p53, Ki-67 and c-erb B2 in growth hormoneand/ or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 2006;64:60-6.
17. Grimm F , Maurus R , Beschorner R, et al. Ki-67 Labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Acta Neurochir (Wien) 2019; 161:1149-56.
18. Badiu C, Dumbrava M, Stancu C, et al. Immunoreactivity for glycoproteic hormones and tumor size in pituitary adenomas. Acta Endocrinol (Buchar) 2006;2:1-9